Sesamin inhibits RANKL‐induced osteoclastogenesis and attenuates LPS‐induced osteolysis via suppression of ERK and NF‐κB signalling pathways

Abstract

AbstractInfection by bacterial products in the implant and endotoxin introduced by wear particles activate immune cells, enhance pro‐inflammatory cytokines production, and ultimately promote osteoclast recruitment and activity. These factors are known to play an important role in osteolysis as well as potential targets for the treatment of osteolysis. Sesamin has been shown to have a variety of biological functions, such as inhibiting inflammation, anti‐tumour and involvement in the regulation of fatty acid and cholesterol metabolism. However, the therapeutic effect of sesamin on osteolysis and its mechanism remain unclear. Present studies shown that in the condition of in vitro, sesamin could inhibit osteoclastogenesis and bone resorption, as well as suppressing the expression of osteoclast‐specific genes. Further studies on the mechanism suggest that the effect of sesamin on human osteoclasts was mediated by blocking the ERK and NF‐κB signalling pathways. Besides, sesamin was found to be effective in treating LPS‐induced osteolysis by decreasing the production of pro‐inflammatory cytokines and inhibiting osteoclastogenesis in vivo. Sesamin was non‐toxic to heart, liver, kidney, lung and spleen. Therefore, sesamin is a promising phytochemical agent for the therapy of osteolysis‐related diseases caused by inflammation and excessive osteoclast activation.